IP Library Granted Patent US 11,229,482
Granted Patent B2
US 11,229,482 · App. 16/192,109 · Granted Jan 25, 2022

Apparatus and methods to modulate bladder function

Inventors: Dan Sachs (Maple Grove, MN); Edwin J. Hlavka (Minneapolis, MN)
Assignee: Hologic, Inc.
A61B18/1492A61B18/04A61B18/1477A61B18/1485A61B18/18A61B18/1815A61B18/24A61F7/12A61B2018/0022A61B2018/00023A61B2018/00083A61B2018/00267A61B2018/00517A61B2018/00523A61B2018/00577A61B2018/143A61B2018/183A61B2018/1861
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,229,482
App. No.
16/192,109
Granted
Jan 25, 2022
Kind
B2
Abstract

Apparatus and methods are provided to concentrate energy delivery in non-superficial target tissue within a trigone region of a human bladder wall to modulate bladder function.

Claims (15)

1. A method to modulate bladder function of a patient, comprising:

introducing a tissue ablation device through a vagina of the patient and into contact with a mucosal surface of an anterior wall of the vagina; and

delivering ablation energy from the tissue ablation device into non-superficial target tissue underneath the mucosal surface, thereby ablating the non-superficial target tissue, without ablating the mucosal surface, wherein the non-superficial target tissue is located within a trigone region of a urinary bladder wall of the patient.

2. The method of claim 1 , wherein the delivered ablation energy comprises at least one of microwave energy, laser energy, cryo energy, ultrasound energy, and electrocautery energy.

3. The method of claim 1 , wherein the ablation of the non-superficial target tissue modulates nerve traffic to or from at least a portion of a urinary bladder of the patient.

4. The method of claim 1 , wherein the ablation of the non-superficial target tissue modulates at least one of a sense of urinary urge, a sense of urgency, a sense of urinary pressure, urinary incontinence, urinary frequency, nocturia, bladder capacity, or pelvic pain.

5. The method of claim 1 , further comprising applying suction to the mucosal surface via a surface of the tissue ablation device, such that the mucosal surface conforms to the surface of the tissue ablation device while the ablation energy is delivered into the non-superficial target tissue via at least one energy delivery element of the tissue ablation device.

6. The method of claim 3 , further comprising repeating the delivery of ablation energy to create circular ablation patterns in the non-superficial target tissue around ureteral ostia of the urinary bladder, and an arc-like ablation pattern in the non-superficial target tissue located about a urethral ostium of the urinary bladder.

7. The method of claim 3 , further comprising repeating the delivery of ablation energy to create a linear ablation pattern in the non-superficial target tissue that circumscribes the trigone region of the urinary bladder.

8. The method of claim 3 , further comprising repeating the delivery of ablation energy to create an ablation pattern that substantially encompasses the trigone region of the urinary bladder.

9. The method of claim 1 , further comprising deploying at least one energy delivery element from the tissue ablation device through the mucosal surface and into the non-superficial target tissue of the urinary bladder wall, wherein the ablation energy is delivered into the non-superficial target tissue via the at least one energy delivery element.

10. The method of claim 9 , wherein the at least one energy delivery element comprises a plurality of energy delivery elements.

11. The method of claim 9 , wherein the at least one energy delivery element is deployed a predetermined depth from the tissue ablation device through the mucosal surface and into the non-superficial target tissue of the urinary bladder wall.

12. The method of claim 9 , wherein the at least one energy delivery element is deployed from the tissue ablation device in a direction parallel to the mucosal surface.

13. The method of claim 9 , wherein the at least one energy delivery element is deployed from the tissue ablation device in a direction perpendicular to the mucosal surface.

Assignments (4)
SECURITY INTEREST Recorded Apr 8, 2026
From: BIOTHERANOSTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; CYTYC CORPORATION; SUROS SURGICAL SYSTEMS, INC.; GYNESONICS, INC.; BOLDER SURGICAL, LLC; FAXITRON BIOPTICS, LLC; HEALTH BEACONS, INC.; HOLOGIC, INC.
To: ROYAL BANK OF CANADA, AS COLLATERAL AGENT
Reel/Frame 075462/0440 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 11, 2019
From: SACHS, DAN; HLAVKA, EDWIN J.
To: AMPHORA MEDICAL, INC.
Reel/Frame 051251/0814 →
SECURITY INTEREST Recorded Oct 14, 2019
From: HOLOGIC, INC.; CYNOSURE, LLC; CYTYC CORPORATION; FAXITRON BIOPTICS, LLC; FOCAL THERAPEUTICS, INC.; GEN-PROBE INCORPORATED
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 050719/0701 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 18, 2019
From: AMPHORA MEDICAL, INC.
To: HOLOGIC, INC.,
Reel/Frame 049786/0138 →